Amneal Pharmaceuticals
AMRX
156 hedge funds and large institutions have $202M invested in Amneal Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 47 reducing their positions, and 27 closing their positions.
1.51% more ownership
Funds ownership: 65.78% → 67.29% (+1.5%)
1% more funds holding
Funds holding: 154 → 156 (+2)
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
2% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 47
1% more capital invested
Capital invested by funds: $200M → $202M (+$2.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less call options, than puts
Call options by funds: $119K | Put options by funds: $149K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$8.55M |
| 2 |
Millennium Management
New York
|
+$6.8M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$6.08M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.61M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.96M |
Top Sellers
| 1 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$8.71M |
| 2 |
EP
Eversept Partners
New York
|
-$8.65M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.55M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.14M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$1.98M |
AMRX Hedge Fund Activity: Q4 2022 in Review
156 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2022, worth a combined $202M — up 1.2% from $200M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AMRX positions and 27 closed out — a net gain of 2 holders — while 48 added to existing stakes and 47 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $8.55M. The largest seller was TPG GP A, cutting an estimated $8.71M.
- 156 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2022, up from 154 in Q3 2022.
- Funds reported $202M of Amneal Pharmaceuticals stock for Q4 2022, up 1.2% quarter-over-quarter.
- 29 funds opened new Amneal Pharmaceuticals positions in Q4 2022 and 27 closed out, a net change of +2 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2022 was Morgan Stanley, an estimated $8.55M added.
- The largest Amneal Pharmaceuticals seller in Q4 2022 was TPG GP A, an estimated $8.71M sold.
Based on aggregated 13F filings for Q4 2022.